Burnie Academy

GLP-1 Medicines and Binge Eating Disorder: The Honest Facts Binge eating disorder (BED) is a real eating disorder, not a willpower problem. The FDA-approved medicine for BED is lisdexamfetamine (Vyvanse), which is not a GLP-1. GLP-1 medicines like semaglutide and liraglutide are being studied for BED because they may reduce appetite and reward-driven eating, but the evidence is small and emerging, and they are not approved for BED. Evidence-based therapy such as cognitive behavioral therapy is the main first-line help. A GLP-1 should not be used for binge eating without eating-disorder screening and a specialist, because misuse can cause serious harm.

GLP-1 medicines and breastfeeding: the honest, careful answer GLP-1 weight-loss medicines like semaglutide and liraglutide are generally not recommended while you are breastfeeding. The FDA labels say there are no data on these drugs in human milk, and rodent studies show the drugs do pass into animal milk. One small study of eight mothers found that injectable semaglutide was not detectable in milk, but the human data are still very limited. The Wegovy tablet form is specifically not recommended during nursing because of an extra ingredient called SNAC. The good news is that breastfeeding itself helps with postpartum weight loss and gives your baby big health benefits. This guide explains what the FDA labels, the LactMed database, and the World Health Organization really say, the postpartum weight-loss question, and the timing of when you might restart. Your doctor and your baby's pediatrician decide your care.

GLP-1 medicines in the menopause transition: honest help and risks Around the menopause transition, estrogen falls and the body shifts more fat to the belly, insulin resistance rises, and bone density starts to drop. GLP-1 medicines like semaglutide are not hormone therapy and do not treat menopause itself, but the small evidence so far in menopausal and postmenopausal women shows they help with weight loss and central belly fat, and may help cardiometabolic risk. Honest gaps remain: menopause-specific data on bone density and muscle preservation are still limited, so protein, strength work, and bone care matter even more while on these medicines. Decisions on dose, hormone therapy, and bone treatment belong with your doctor.

GLP-1 for normal BMI: the honest ethics and safety picture GLP-1 medicines like semaglutide were built for medical obesity and type-2 diabetes, not for dropping a few kilos before a wedding. The official rule is clear: a doctor may prescribe for weight loss only if your BMI is 30 or more, or 27 or more with a weight-related condition like diabetes or high blood pressure. Indian and South-Asian cut-points are lower, around 23 for overweight and 25 for obesity, but they are still medical criteria, not a cosmetic pass. This guide gives the honest picture on who really qualifies, why cosmetic and low-BMI use is not recommended, the real risks in lean bodies, the shortage and access ethics, and what to do instead. Always talk to your doctor. This article does not tell you to take any medicine.

GLP-1 medicines for older adults: who benefits, what to watch Type 2 diabetes and extra weight are common in older adults, and GLP-1 medicines like semaglutide and tirzepatide can help with blood sugar, weight, and heart and kidney protection. But older bodies handle medicines differently. Kidney function falls with age, side effects like nausea and appetite loss can tip into undernutrition instead of healthy weight loss, and many older adults take several medicines at once, which raises the chance of interactions and low blood sugar. The honest picture is that GLP-1 medicines can be a good fit for many older adults when a doctor leads the care, with slower dose changes, nutrition-preserving weight loss, protein and strength work, and regular kidney and medicine review.

GLP-1 medicines and pregnancy planning: stop before you try GLP-1 weight-loss medicines like semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda) should not be used during pregnancy or when you are trying to conceive. The labels say to stop semaglutide at least 2 months before a planned pregnancy because the medicine stays in the body a long time, and to stop the moment a pregnancy is recognised. Use reliable contraception while on the medicine so you do not get pregnant before the washout is complete. Preconception weight loss can help fertility and lower pregnancy risk, but the drug itself is stopped. Your doctor decides your exact plan.

GLP-1 medicines and your thyroid: the C-cell warning GLP-1 weight-loss medicines like semaglutide, liraglutide and tirzepatide carry a real FDA boxed warning about thyroid C-cell tumors, but the warning is built on rat and mouse studies, and the labels plainly say it is unknown whether these drugs cause such tumors, including medullary thyroid carcinoma, in humans. The drugs are firmly contraindicated if you have, or have a family history of, medullary thyroid carcinoma or the inherited condition MEN 2. For everyone else, large pooled trial data so far have not shown a clear rise in thyroid cancer, and routine calcitonin or ultrasound monitoring is judged to be of uncertain value. The practical point that often gets missed: GLP-1 drugs slow stomach emptying, which can change how well your body absorbs levothyroxine, so thyroid hormone timing and TSH checks need attention when you start. This guide is honest about what the warning does and does not mean.

Why GLP-1 medicines are not standard treatment for type 1 diabetes Type 1 diabetes is a different disease from type 2. In type 1, the immune system destroys the beta cells that make insulin, so the body makes little or no insulin. GLP-1 medicines like Ozempic and Mounjaro work partly by telling the body to release insulin when blood sugar rises. When the beta cells are gone, that benefit is limited. These medicines are not approved for type 1 diabetes and are not a replacement for insulin. Some small studies looked at GLP-1 as an add-on to insulin in type 1, with modest sugar, weight and insulin-dose benefits, but they also saw more low sugars and ketosis risk. Insulin remains the foundation of type 1 care. This is a plain explainer, not medical advice; your diabetologist decides.

GLP-1 medicines, craving, and addiction: emerging, not approved Early research hints that GLP-1 medicines like semaglutide, liraglutide, and exenatide may quiet the brain's reward pathways and reduce alcohol craving, smoking reward, and possibly some behavioural addictions. This is promising but preliminary: small trials, animal data, and large observation studies. No GLP-1 medicine is approved to treat alcohol use disorder, smoking, or gambling, and larger trials are still running. This honest guide explains what the science shows and what it does not.

GLP-1 medicines and blood pressure: a small, honest benefit GLP-1 medicines like semaglutide and liraglutide do lower blood pressure a little, but the effect is modest. Large reviews of many trials show these drugs bring systolic blood pressure (the top number) down by about 3 mmHg on average, not the big drop people sometimes imagine. Some of that fall comes from the weight you lose on the medicine, and some comes from the kidneys releasing more salt and water, a process called natriuresis. This guide gives the honest picture: a GLP-1 is a small helper for blood pressure, never a replacement for your blood pressure tablets. Your doctor decides your care, and you should never stop blood pressure medicine on your own.

GLP-1 medicines and cholesterol: what lipid trials show GLP-1 shots like semaglutide, liraglutide and tirzepatide are famous for weight loss and blood sugar control. A fair question is whether they also fix cholesterol and blood fats. The honest answer from pooled trials: they modestly lower triglycerides and LDL a little, and much of that rides on the weight loss. They are not a replacement for statins. Statins stay the main tool for lowering heart risk from cholesterol. Here is what the data really show, where they fall short, and what to ask your doctor.

GLP-1 Medicines and Fatty Liver (MASH): What the Trials Show GLP-1 medicines like semaglutide and tirzepatide can cut liver fat and ease MASH. Wegovy is now FDA-approved for MASH with liver scarring. Here is what trials show, the limits, and why weight loss drives the liver benefit.

GLP-1 medicines and heart health: what trials really show Large trials tested GLP-1 shots like semaglutide and liraglutide for heart outcomes. Here is what they showed, who they helped, and what they do not prove about replacing your other heart medicines.

GLP-1 medicines and the brain: early Alzheimer signals Some studies hint that GLP-1 medicines, used for diabetes and weight loss, may protect the brain and slow memory decline in early Alzheimer's disease. The signals are real and worth watching, but they are early. No GLP-1 medicine is approved for dementia, and the largest trial so far did not show a clear clinical benefit. This guide gives the honest picture: what the trials found, what the biology suggests, and what it means for you.

GLP-1 weight loss and knee osteoarthritis: the honest picture Carrying extra weight loads the knees and hips with extra force every step, and that raises the risk of osteoarthritis pain and joint damage. Losing weight takes that load off, and the more weight you lose, the more the knee pain eases. GLP-1 medicines like semaglutide can help by producing real weight loss. In the STEP 9 trial of semaglutide in people with obesity and knee osteoarthritis, the medicine group lost more weight and had more knee pain relief than the placebo group, who also got diet and activity advice. The honest part is that this benefit is mostly driven by weight loss itself, not by any special joint-healing effect. GLP-1 is not a disease-modifying osteoarthritis drug; it does not regrow cartilage or undo joint damage that is already there. Physical therapy, exercise and weight loss remain the core of knee and hip osteoarthritis care.

GLP-1 medicines and PCOS: weight, insulin, and fertility PCOS often brings insulin resistance and weight gain that make periods irregular and fertility hard. GLP-1 medicines like liraglutide and semaglutide are being used off-label to help women with PCOS lose weight and improve periods, but the proof comes from small trials, they are not a cure, and they must be stopped before pregnancy.

GLP-1 medicines and prediabetes: can they delay diabetes? Prediabetes means your blood sugar is above normal but not yet high enough to be type 2 diabetes (HbA1c 5.7 to 6.4 percent). GLP-1 medicines like Ozempic and Mounjaro can help push weight and blood sugar down, and for some people that can drop HbA1c below the prediabetes range. But the proven backbone for preventing diabetes is still the Diabetes Prevention Program lifestyle plan, which cut new diabetes by 58 percent, with metformin next at 31 percent. GLP-1s are an adjunct, not a replacement. Stopping them usually means weight returns, and the STEP 1 extension shows the blood-sugar gains slip back too. Your doctor decides if a GLP-1 fits you on top of food, activity, and metformin.

GLP-1 medicines and sleep apnoea: the honest picture Obstructive sleep apnoea, where the airway partly or fully closes during sleep, is common in people carrying extra weight, because extra tissue around the neck narrows the airway. Losing weight is one of the few things that can actually reduce sleep apnoea severity, and a 10 percent drop in body weight can cut the apnoea count by about a quarter to a third. The SURMOUNT-OSA trial of tirzepatide in adults with obesity and moderate-to-severe sleep apnoea found a large drop in the apnoea count compared with placebo, on top of weight loss. Semaglutide has less direct apnoea-count evidence so far, mostly from observational data. The honest line is this: these medicines can help sleep apnoea mainly through weight loss, they are not a replacement for CPAP, and many people still need CPAP even after losing weight.

GLP-1 weight loss and your bones: the honest picture Losing weight, by any method, tends to reduce bone density a little, and rapid large weight loss raises the bigger concern for fractures. For GLP-1 medicines like semaglutide, animal studies raised a worry, but human trials and meta-analyses so far have not shown a clear increase in clinical fractures, and some data suggest GLP-1 may modestly protect bone compared with plain calorie cutting. To keep bones safe during weight loss, get enough calcium, vitamin D and protein, and do weight-bearing and strength exercise, not just diet.

GLP-1 and suicidal thoughts: reviewed, no link found, still monitor In 2023, a safety signal raised the question of whether GLP-1 medicines such as semaglutide and liraglutide might be linked to suicidal thoughts or self-harm. Regulators took it seriously: Europe's medicines agency reviewed the evidence and closed the signal in April 2024, and large real-world studies have not found a causal link. This guide gives the honest picture and explains why mood monitoring still matters.

GLP-1 medicines and gallstones: the honest risk picture GLP-1 weight-loss medicines like semaglutide, tirzepatide and liraglutide do raise the risk of gallbladder problems, and the official medicine labels list gallstones as a side effect. The risk goes up with faster weight loss and higher doses, but it is usually manageable and for the right patient the benefits often outweigh it. Here is what the labels and studies actually say, the warning signs to watch for, and how to talk to your doctor.

GLP-1 and slow stomach: when nausea is normal, when it is not GLP-1 medicines like Ozempic and Wegovy slow your stomach on purpose. That is how they cut appetite and after-meal sugar spikes, so mild nausea and early fullness are expected in most people. But severe vomiting, feeling full for hours, bloating, or not passing gas or stool can be gastroparesis or ileus, which need urgent care. The FDA has added warnings to this class for these serious gut effects, and people who already have gastroparesis or long-standing diabetic nerve damage are usually kept off these medicines.

GLP-1 weight loss and hair shedding: honest telogen effluvium story Hair thinning or extra shedding reported with GLP-1 weight loss is mostly telogen effluvium, the same temporary hair loss seen after any rapid weight loss, bariatric surgery, crash diet, or severe stress. It is not a special GLP-1 toxicity on your hair follicles. Losing weight gradually, eating enough protein, iron and zinc, and not crashing your calories reduces it, and it usually grows back on its own. See a doctor if the shedding is heavy or lasts many months.

GLP-1 and your kidneys: protection plus a dehydration warning GLP-1 medicines like semaglutide and liraglutide have shown real kidney-protective effects in people with type 2 diabetes, lowering the risk of kidney failure and worsening kidney disease in major trials. At the same time, the medicine labels warn that severe vomiting or diarrhoea from these drugs can cause dehydration and, in some cases, acute kidney injury, especially in people who already have kidney disease. The honest picture is both: long-term kidney protection in diabetes, plus a real dehydration risk you can lower by drinking fluids and reporting severe gut side effects early.

GLP-1 medicines and pancreatitis: the honest, rare-but-serious risk Pancreatitis, inflammation of the pancreas, is a listed warning on every GLP-1 label. The labels report that acute pancreatitis, including fatal, hemorrhagic or necrotising cases, has been observed in patients treated with GLP-1 receptor agonists, and say to stop the medicine if pancreatitis is suspected. At the same time the labels describe it as rare, and a 2024 meta-analysis found only a modestly raised relative risk of about 1.44. So this is a real, label-listed, rare-but-serious risk: do not ignore it, and do not panic over it either.

GLP-1 medicines and diabetic retinopathy: the honest eye story A large semaglutide trial called SUSTAIN-6 found a small increase in diabetic retinopathy complications, with a hazard ratio of about 1.76. This is thought to be partly linked to a fast drop in blood sugar, because rapid improvement in glucose control can cause a temporary worsening of retinopathy, a known effect of intensive diabetes treatment and not unique to GLP-1 medicines. The honest picture is that people with existing diabetic retinopathy should be monitored with eye checks when starting a GLP-1 and tightening sugar control, while the long-term effect of good sugar control is to reduce retinopathy. Talk to your diabetologist and your eye doctor.

GLP-1 muscle loss: why ~25% of weight lost is lean mass When you lose weight on a GLP-1 medicine like semaglutide or tirzepatide, about a quarter of the weight you lose is lean mass, not fat. This is true of weight loss in general, but the large and fast losses seen with GLP-1 make it matter more, especially for older adults. Losing muscle can lower your strength, your day-to-day function, and your metabolic rate. The answer is not to avoid GLP-1, but to pair it with enough protein, resistance training, and, if you can, body-composition tracking like a DEXA scan, because a bathroom scale cannot tell muscle from fat.

Ozempic face: it's weight loss, not a drug effect on your face Ozempic face is the hollow cheeks, sagging skin and older look some people notice after losing a lot of weight on GLP-1 medicines. It is not a special toxic effect of the drug on your face. It is the loss of facial fat that comes with any large, fast weight loss, the same thing that happens after bariatric surgery or strict dieting. How much it shows depends on how much and how fast you lose, and on your age and skin. You can soften it by losing weight more slowly, eating enough protein, doing strength training, and, if you want, cosmetic dermatology later. The medical priority is the health gain from the weight loss.

Bupropion for weight loss: off-label, and the seizure risk is real Bupropion is an antidepressant that tends to cause slight weight loss rather than weight gain, which is why people ask about it for weight. Used alone for weight loss it is off-label and the effect is modest. The bigger, honest reason it is not a casual weight-loss drug is that it lowers the seizure threshold in a dose-dependent way. In India bupropion is available for depression and smoking cessation, but using it alone for weight loss is uncommon and off-label. Please talk to your doctor before any decision.

Contrave (naltrexone/bupropion) for weight loss: honest guide Contrave is a US FDA-approved weight-loss pill that pairs two older medicines, naltrexone and bupropion, into one extended-release tablet. It works on brain pathways that control hunger and food reward, and the honest weight-loss result in trials was modest, around 5 to 8 percent of body weight. It is not approved or marketed in India as a standard combination, and it carries real risks, including seizures from bupropion and rising blood pressure. This guide gives the plain picture and tells you to ask your doctor.

Read every article for free

Track your food the honest way